Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease

摘要

Genetic biomarkers for left side colon cancer (LCC) (such as expression levels of an RNA transcript or expression product of NOX4, MMP3, or a combination) and right side colon cancer (RCC) (such as expression levels of an RNA transcript or expression product of CDCX2, FAM69A, or a combination), are disclosed. Methods for using the biomarkers in providing a prognosis of relapse-free survival probability in patients having LCC or RCC are also presented. Prognostic panels using gene expression values of the biomarkers are also presented. Computer implemented methods employing the biomarkers, and as well as for determining relapse-free survival probability in a patient having RCC or LCC are provided. A genetic method for classifying a colon cancer tissue as a RCC or as a LCC is also disclosed.

主权项

1. A panel of probes for indicating a 5-year left-side colon cancer (LCC) relapse probability of LCC in a post-surgery human LCC patient, said panel of probes consisting of detectably labeled single-stranded polynucleotides complementary to mRNA or cDNA of two or more genes selected from the group consisting of NOX4, MMP3, SLC16A6, WNT5A, CYP1B1, IBSP, TFAP2C, MATN3 and ANKRD6.